NCT04906382 2025-02-13
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
Ohio State University Comprehensive Cancer Center
Cedars-Sinai Medical Center
Case Comprehensive Cancer Center
University of California, San Francisco